Literature DB >> 25068571

Successful catheter ablation decreases platelet activation and improves endothelial function in patients with atrial fibrillation.

Han S Lim1, Scott R Willoughby1, Carlee Schultz1, Adhiraj Chakrabarty1, Muayad Alasady1, Dennis H Lau1, Kurt C Roberts-Thomson1, Matthew I Worthley1, Glenn D Young1, Prashanthan Sanders2.   

Abstract

BACKGROUND: Nonvalvular atrial fibrillation (AF) confers a five-fold increased risk of stroke. Whether catheter ablation (CA) subsequently decreases prothrombotic risk is unknown.
OBJECTIVE: The purpose of this study was to assess the long-term effects of CA for AF on prothrombotic risk.
METHODS: Fifty-seven patients undergoing CA for AF were prospectively studied. Platelet activation (CD62P [platelet P-selectin] and PAC-1 [glycoprotein IIb/IIIa] expression) and endothelial function (asymmetric dimethylarginine [ADMA] levels) were measured at baseline and 6-months postablation.
RESULTS: Thirty-seven (65%) patients remained in sinus rhythm (SR group) and 20 (35%) sustained AF recurrence (AF recurrence group) at 6-months. Patients with AF-recurrence were older, had a higher proportion of hypertension and long-standing persistent AF. There were no significant differences in CD62P (P = .3), PAC-1 (P = .1) and ADMA (P = .7) levels at baseline between the two groups. In the SR group, markers of platelet activation decreased significantly at 6-month follow-up compared to baseline; log CD62P % 0.79 ± 0.28 vs 1.03 ± 0.27 (P <.05) and log PAC-1 % 0.22 ± 0.58 vs 0.89 ± 0.31 (P <.01). This was not significant in the AF-recurrence group (P = .8, log CD62P; P = .1, log PAC-1). For endothelial function, ADMA levels decreased significantly at 6-months compared to baseline in the SR group (log ADMA μM/L 0.15 ± 0.02 vs 0.17 ± 0.04; P <.05), but did not alter significantly in the AF-recurrence group (P = .4, log ADMA).
CONCLUSION: Catheter ablation and successful maintenance of SR leads to a decrease in platelet activation and improvement in endothelial function in patients with AF. These findings suggest that AF is an important determinant of the prothrombotic state and that this may be reduced by successful catheter ablation. Crown
Copyright © 2014. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atrial fibrillation; Catheter ablation; Endothelial dysfunction; Platelet activation; Stroke prevention; Thrombotic risk

Mesh:

Substances:

Year:  2014        PMID: 25068571     DOI: 10.1016/j.hrthm.2014.07.030

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  9 in total

Review 1.  Role of inflammation in atrial fibrillation pathophysiology and management.

Authors:  Masahide Harada; David R Van Wagoner; Stanley Nattel
Journal:  Circ J       Date:  2015-02-16       Impact factor: 2.993

2.  Recovery of renal dysfunction after catheter ablation of outflow tract ventricular arrhythmias in patients with ventricular premature depolarization-mediated cardiomyopathy.

Authors:  Shingo Maeda; William W Chik; Jackson J Liang; Iosif Kelesidis; Ruben Casado Arroyo; Benjamin D'Souza; Mouhannad M Sadek; Daniele Muser; Fabien Squara; Deviprasad Venugopal; Pasquale Santangeli; David S Frankel; Erica S Zado; Francis E Marchlinski; David J Callans
Journal:  J Interv Card Electrophysiol       Date:  2016-10-10       Impact factor: 1.900

3.  Biomarkers in the clinical management of patients with atrial fibrillation and heart failure.

Authors:  Ioanna Koniari; Eleni Artopoulou; Dimitrios Velissaris; Mark Ainslie; Virginia Mplani; Georgia Karavasili; Nicholas Kounis; Grigorios Tsigkas
Journal:  J Geriatr Cardiol       Date:  2021-11-28       Impact factor: 3.327

4.  Left ventricular native T1 time and the risk of atrial fibrillation recurrence after pulmonary vein isolation in patients with paroxysmal atrial fibrillation.

Authors:  Shingo Kato; Murilo Foppa; Sébastien Roujol; Tamer Basha; Sophie Berg; Kraig V Kissinger; Beth Goddu; Warren J Manning; Reza Nezafat
Journal:  Int J Cardiol       Date:  2015-11-11       Impact factor: 4.164

5.  Asymmetric dimethylarginine, related arginine derivatives, and incident atrial fibrillation.

Authors:  Renate B Schnabel; Renke Maas; Na Wang; Xiaoyan Yin; Martin G Larson; Daniel Levy; Patrick T Ellinor; Steven A Lubitz; David D McManus; Jared W Magnani; Dorothee Atzler; Rainer H Böger; Edzard Schwedhelm; Ramachandran S Vasan; Emelia J Benjamin
Journal:  Am Heart J       Date:  2016-03-17       Impact factor: 4.749

6.  Catheter ablation for AF improves global thrombotic profile and enhances fibrinolysis.

Authors:  Maria Niespialowska-Steuden; Vias Markides; Mohamed Farag; David Jones; Wajid Hussain; Tom Wong; Diana A Gorog
Journal:  J Thromb Thrombolysis       Date:  2017-11       Impact factor: 2.300

7.  Si-Miao-Yong-An Decoction Protects Against Cardiac Hypertrophy and Dysfunction by Inhibiting Platelet Aggregation and Activation.

Authors:  Congping Su; Qing Wang; Huimin Zhang; Wenchao Jiao; Hui Luo; Lin Li; Xiangyang Chen; Bin Liu; Xue Yu; Sen Li; Wei Wang; Shuzhen Guo
Journal:  Front Pharmacol       Date:  2019-09-18       Impact factor: 5.810

8.  Data for short and long-term prothrombotic biomarkers after cryoballoon and radiofrequency ablation.

Authors:  Khalid Bin Waleed; Lili Wang; Gary Tse; Xiaomeng Yin; Xiaolei Yang; Bailing Dai; Yang Liu; Zhao Wang; Xumin Guan; Lianjun Gao; De Greef Yves; Riccardo Cappato; Shulin Wu; Yunlong Xia
Journal:  Data Brief       Date:  2019-06-05

9.  The Neuronal Transcription Factor Creb3l1 Potential Upregulates Ntrk2 in the Hypertensive Microenvironment to Promote Vascular Smooth Muscle Cell-Neuron Interaction and Prevent Neurons from Ferroptosis: A Bioinformatic Research of scRNA-seq Data.

Authors:  Xiaoyu Zhao; Jie Yang; Chuanhua Yang
Journal:  Dis Markers       Date:  2022-02-10       Impact factor: 3.434

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.